Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma

Knowledge of oncogenic mutations can inspire therapeutic strategies that are synthetically lethal, affecting cancer cells while sparing normal cells. Lenalidomide is an active agent in the activated B-cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL), but its mechanism of action is un...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Yang, Yibin, Shaffer, Arthur L., Emre, N.C. Tolga, Ceribelli, Michele, Zhang, Meili, Wright, George, Xiao, Wenming, Powell, John, Platig, John, Kohlhammer, Holger, Young, Ryan M., Zhao, Hong, Yang, Yandan, Xu, Weihong, Buggy, Joseph J., Balasubramanian, Sriram, Mathews, Lesley A., Shinn, Paul, Guha, Rajarshi, Ferrer, Marc, Thomas, Craig, Waldmann, Thomas A., Staudt, Louis M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2012
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4059833/
https://ncbi.nlm.nih.gov/pubmed/22698399
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccr.2012.05.024
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia